SCHEMBL1122374

SCHEMBL1122374

COc1cc(/C=C/S(=O)(=O)Cl)cc(OC)c1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.59
CYP1A1 P04798 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP1B1 Q16678 1/20 0.55
GAA P10253 1/20 0.54
HTT P42858 1/20 0.54
KDM4E B2RXH2 1/20 0.54
ALDH1A1 P00352 1/20 0.54
HTR1A P08908 1/20 0.54
HPGD P15428 1/20 0.54
HTR2C P28335 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TUBB1 Q9H4B7 9/20 0.53
TUBB4A P04350 7/20 0.53
TUBB P07437 7/20 0.53
TUBA3C P0DPH7 7/20 0.53
TUBA1B P68363 7/20 0.53
TUBA4A P68366 7/20 0.53
TUBB4B P68371 7/20 0.53
TUBB3 Q13509 7/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1122375 1.00 EGFR (0.59) EGFRCYP1A1CYP1A2CYP1B1GAA
SCHEMBL1324310 0.81 EGFR (0.59) EGFRCYP1A1CYP1A2CYP1B1GAA
SCHEMBL1324314 0.81 EGFR (0.59) EGFRCYP1A1CYP1A2CYP1B1GAA
SCHEMBL1324945 0.80 EGFR (0.58) EGFRCYP1A1CYP1A2CYP1B1GAA
SCHEMBL1324981 0.80 EGFR (0.58) EGFRCYP1A1CYP1A2CYP1B1GAA
SCHEMBL1324862 0.80 EGFR (0.58) EGFRCYP1A1CYP1A2CYP1B1GAA
SCHEMBL1324370 0.80 EGFR (0.58) EGFRCYP1A1CYP1A2CYP1B1GAA
SCHEMBL1324870 0.80 EGFR (0.58) EGFRCYP1A1CYP1A2CYP1B1GAA
SCHEMBL1324979 0.80 EGFR (0.58) EGFRCYP1A1CYP1A2CYP1B1GAA
SCHEMBL1324371 0.80 EGFR (0.58) EGFRCYP1A1CYP1A2CYP1B1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379508-B9 N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF UNIV TEMPLE (US) 2011-02-09 EP disclosed
US-6646009-B2 Use against proliferative disorders including cancer, and as a radioprotective compound for normal cells from ionizing radiation Temple University — Of Commonwealth System of Higher Education 2003-11-11 US disclosed